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Abstract
Severe systemic inflammatory response to infection results in severe sepsis and septic shock, which are the leading
causes of death in critically ill patients. Septic shock is characterised by refractory hypotension and is typically managed
by fluid resuscitation and administration of catecholamine vasopressors such as norepinephrine. Vasopressin can also
be administered to raise mean arterial pressure or decrease the norepinephrine dose. Endogenous norepinephrine and
vasopressin are synthesised by the copper-containing enzymes dopamine β-hydroxylase and peptidylglycine
α-amidating monooxygenase, respectively. Both of these enzymes require ascorbate as a cofactor for optimal
activity. Patients with severe sepsis present with hypovitaminosis C, and pre-clinical and clinical studies have
indicated that administration of high-dose ascorbate decreases the levels of pro-inflammatory biomarkers, attenuates
organ dysfunction and improves haemodynamic parameters. It is conceivable that administration of ascorbate to
septic patients with hypovitaminosis C could improve endogenous vasopressor synthesis and thus ameliorate the
requirement for exogenously administered vasopressors. Ascorbate-dependent vasopressor synthesis represents a
currently underexplored biochemical mechanism by which ascorbate could act as an adjuvant therapy for severe
sepsis and septic shock.

Introduction
Sepsis is a potentially life-threatening systemic inflammatory response to infection which can result in multisystem organ dysfunction (severe sepsis) and refractory
hypotension (septic shock) [1]. Sepsis is a complex, heterogeneous condition that can be caused by any infectious organism, with Gram-positive infections often
predominating [2]. A majority of septic patients have a
pulmonary source of infection, such as pneumonia,
which results in acute respiratory distress syndrome [1].
Dysfunction of cardiovascular, hepatic, renal and central
nervous systems can also occur in severe sepsis [3]. The
incidence of severe sepsis is increasing, due to an increasingly aging population [4], and is currently the leading cause of death in critically ill patients, with mortality
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rates of 30–50 % [5]. The Surviving Sepsis Campaign
has recommended a number of strategies for the management of severe sepsis and septic shock, including fluid resuscitation, infection control, and respiratory and central
nervous system support [6] and, despite an increase in incidence, mortality rates appear to be declining [7].
Septic shock is characterised by severe alterations in
the cardiovascular system, including ineffective tissue
oxygenation, inappropriate peripheral vasodilation, myocardial dysfunction and altered blood flow distribution,
resulting in hypotension refractory to intravenous fluid
administration [1, 8]. Septic shock is typically managed
through the administration of catecholamine vasopressors (dopamine, norepinephrine or epinephrine), with
norepinephrine being the preferred vasoconstrictor [9].
Vasopressin is also recommended in the Surviving Sepsis
Campaign guidelines to raise mean arterial pressure to
target or to decrease the norepinephrine dose [6]. The
Vasopressin and Septic Shock Trial (VASST) indicated
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that vasopressin provided equivalent mortality rates to
norepinephrine in patients already receiving vasopressors [10]. Exogenous vasopressor administration to patients with severe sepsis and septic shock, however, can
result in adverse side effects such as decreased cardiac
output and cardiac arrest, mesenteric ischaemia, skin necrosis, digital ischaemia and hyponatraemia [11].
Recent pre-clinical and clinical studies have indicated
a potential role for ascorbate in ameliorating the pathophysiology of sepsis [12–14]. Numerous studies of septic
animals administered high-dose ascorbate have shown
improved microvascular changes and survival (reviewed
in [14]). A number of mechanisms have been proposed
for ascorbate’s observed activities in sepsis, but these
have primarily focused on its antioxidant and antiinflammatory functions, including its effects on signal
transduction pathways in vascular cells (reviewed in
[13]). In contrast, very little attention has been paid to
ascorbate’s enzyme cofactor activities, particularly its
role in the synthesis of vasopressors [15]. In this review
we present the hypothesis that adjuvant ascorbate could
support endogenous vasopressor synthesis in severe sepsis and septic shock through acting as an essential cofactor for the metallo-enzymes involved in the biosynthesis
of vasoactive catecholamines and vasopressin.

Ascorbate requirements in sepsis
Ascorbate is an essential micronutrient with numerous
important enzyme cofactor functions in the body [15, 16],
as well as potent antioxidant properties [17, 18]. Humans
have lost the ability to synthesise ascorbate due to mutations in the gene encoding the terminal biosynthetic enzyme, and ascorbate must therefore be obtained regularly
through the diet to prevent hypovitaminosis C and the potentially fatal deficiency disease scurvy. Recommended
dietary intakes for ascorbate are typically in the range of
75–110 mg/day [19, 20]. Enteral or parenteral nutrition
administered to critically ill patients provides ~100 mg/
day ascorbate. However, critically ill patients probably require significantly higher intakes of ascorbate [21] due to
enhanced metabolic turnover of vitamin C during the severe inflammatory response. It should also be noted that
parenteral rather than enteral nutrition may be required
for optimal ascorbate status in critically ill patients because intravenously administered ascorbate bypasses the
rate-limiting intestinal uptake of orally administered ascorbate [22].
In healthy fasting humans, circulating levels of ascorbate are typically in the range of 50–70 μmol/l, whereas
levels <23 μmol/l are considered marginally deficient (or
hypovitaminosis C) and levels <11 μmol/l are considered
severely deficient and potentially scorbutic [23]. Several
studies have shown that ascorbate levels are low in critically ill patients (i.e. <23 μmol/l), including those with
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acute respiratory infections [24] and sepsis [12, 25], and
are particularly low (i.e. <11 μmol/l) in patients who
progress to multiple organ failure [26]. In some studies,
ascorbate levels remained lower than those in controls,
despite the patients receiving 100–500 mg/day ascorbate
either enterally or parenterally [27, 28]. Long et al. [27]
demonstrated that up to 3000 mg/day ascorbate was required to return plasma levels of critically ill patients to
normal (i.e. 68 μmol/l).
Interestingly, in animals that are able to synthesise ascorbate in their livers, studies have shown increased endogenous synthesis of ascorbate when the animals are
exposed to stress [29, 30]. We have also observed enhanced mRNA expression of the ascorbate synthesising
enzyme gulonolactone oxidase in lipopolysaccharidetreated mice (R. Natarajan, unpublished observations).
Enhanced ascorbate synthesis has also recently been
shown in mice exposed to tumour burden [31]. These
studies suggest an important physiological requirement
for ascorbate in conditions of stress and disease burden.
Other studies have shown up to an eight-fold enhancement in the synthesis of ascorbate in animals exposed
to drugs, including hypnotics (sedatives), analgesics and
muscle relaxants [32, 33], probably as a compensatory
mechanism for enhanced metabolism of ascorbate following drug administration [33]. Therefore, it is conceivable that patients with severe infection in intensive
care may have enhanced ascorbate requirements not only
due to the infectious disease process, but also because of
the administration of sedatives and other drugs.

Ascorbate’s role in vasopressor synthesis
Cases of scurvy, the clinical presentation of severe ascorbate deficiency, have been reported in critically ill patients in intensive care (Table 1) [34–36]. One case
presented with multiple organ dysfunction and the intravenous administration of ascorbate resulted in improved
cardiovascular functioning within 24 h, particularly increased arterial pressure, decreased heart rate, normalised central venous pressure and a decreased need for
catecholamines [35]. Another case exhibited typical symptoms of scurvy as well as severe orthostatic hypotension
that failed to respond to fluids [36]. The patient’s ascorbate levels were undetectable and the orthostatic
hypotension resolved within 24 h of ascorbate replacement. The authors suggested that the pathogenesis of
orthostatic hypotension in the setting of scurvy could result from impaired catecholamine synthesis. Vasopressin
may also play a role in preventing or minimising
orthostatic hypotension [37], indicating a possible link
between ascorbate deficiency and vasopressin insufficiency in this case [36]. High-dose intravenous ascorbate administration to severely burned patients has
been shown to decrease the resuscitation volume
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Table 1 Summary of studies of ascorbate administration with vasopressor-related endpoints
Study type

Study group

Intervention

Pre-clinical

24 rats (8/group)

Centrally administered ascorbate ↑ vasopressin release
(0, 200, 600 nmol)

Findings

Reference
[62]

↑ antidiuresis
↑ natriuresis
Case report

Hospital patient

Intravenous ascorbate
(1,500 mg/day)

↑ arterial pressure

[35]

↓ heart rate
Normalised central venous
pressure
↓ need for catecholamines
Improved multiple organ
dysfunction
Case report

Hospital patient

Oral ascorbate (500 mg/day)

Resolution of orthostatic
hypotension

[36]

Clinical (retrospective)

33 severely burned patients
(16–17/group)

Intravenous ascorbate
(0, 66 mg/kg/h)

↓ fluid requirement

[39]

↓ number of patients requiring
vasopressors
Clinical (randomised, prospective) 37 severely burned patients
(17–18/group)

Intravenous ascorbate
(0, 66 mg/kg/h)

↓ resuscitation fluid volume

[38]

↑ diuresis
↓ length of mechanical
ventilation
Clinical (phase I randomised
controlled trial)

24 severe sepsis patients
(8/group)

Intravenous ascorbate
(0, 50, 200 mg/kg/24 h)

↓ systemic organ failure

[12]

↑ systolic blood pressurea
↑ mean arterial pressurea
a

Previously unpublished data (R. Natarajan and A. Fowler)
↑ increase, ↓ decrease

required [38] and also to decrease the need for vasopressors in some patients (Table 1) [39].
The recent phase I randomised controlled trial in 24
patients with severe sepsis who were administered
intravenous infusions of ascorbate (0, 50 or 200 mg/kg/
24 h) showed prompt reductions in Sequential Organ
Failure Assessment scores in those receiving ascorbate
[12]. A significant reduction in the pro-inflammatory
biomarkers C-reactive protein and procalcitonin was
also observed, as well as attenuation of thrombomodulin levels, suggesting amelioration of vascular endothelial injury. No adverse safety events were observed in
this study. Previously unpublished data from this trial
indicated an increase in systolic blood pressure and
mean arterial pressure in the group that received
200 mg/kg/24 h ascorbate (Fig. 1a, b). Although these
values did not reach statistical significance, probably
due to low patient numbers, this finding lends support
to our hypothesis that administration of ascorbate
could aid in endogenous vasopressor synthesis.

Ascorbate and catecholamine synthesis

Catecholamine neurotransmitters and hormones (dopamine, norepinephrine and epinephrine) are synthesised
within the sympathetic nervous system and the adrenal
medulla (an organ with a very high ability to store vitamin
C). Catecholamines increase arterial pressure through
binding to and activating α-adrenergic receptors on the
smooth muscle cells of the vasculature and can promote
increased cardiac contractility and heart rate through
binding to β-adrenergic receptors of the cardiac muscle
[40]. During sepsis, myocardial depression commonly occurs due to downregulation of β-adrenergic receptors and
related cell signalling pathways [41]. Impaired adrenal
hormone synthesis has also been observed in critically
ill patients and is probably a common complication in
severe sepsis [42, 43]. Interestingly, norepinephrine
levels are decreased in ascorbate-deficient animal
models, particularly in the adrenal glands [44–46]. Ascorbate is also secreted from the adrenal glands as part
of the stress response [47], which could conceivably
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enhances the synthesis of tyrosine hydroxylase itself
[50]. Ascorbate has also been shown to enhance both αadrenergic and β-adrenergic receptor activity through
binding to the receptor, thereby enhancing its activation
by epinephrine [51, 52].
It is noteworthy that tissues where catecholamines are
synthesised contain the highest levels of ascorbate in the
body (i.e. the brain and adrenal glands) [53], indicating
that vitamin C plays a vital role in these organs. Furthermore, animal models of ascorbate deficiency have shown
significant retention of the vitamin in the brain during
dietary depletion [54–56], supporting the importance of
ascorbate in the central nervous system. Thus, appropriate supplementation of ascorbate in sepsis may support
endogenous synthesis of vasoactive catecholamines, and
possibly also facilitate adrenergic receptor binding.
Ascorbate and vasopressin synthesis

Fig. 1 Effect of ascorbate administration on (a) systolic blood pressure
and (b) mean arterial pressure in patients with severe sepsis. Patients
were administered placebo (circle, 5 % dextrose and water, n = 6) or
ascorbate (inverted triangle, 200 mg/kg/24 h, n = 7). The ascorbate
dosage was divided into four equal doses and administered over
30 min every 6 h for 96 h in 50 ml of 5 % dextrose and water [12].
Systolic blood pressure and mean arterial pressure were measured at
the bedside using an arterial line (radial artery)

result in adrenal ascorbate depletion under conditions
of sustained stress.
Ascorbate is required for two enzymatic steps along
the catecholamine biosynthetic pathway (Fig. 2). Specifically, ascorbate is a cofactor for the copper-containing
enzyme dopamine β-hydroxylase [48, 49]. This enzyme
utilises oxygen to introduce a hydroxyl group to dopamine to form norepinephrine (Fig. 2). Epinephrine can
then be formed via methyltransferase-catalysed methylation of the amine group of norepinephrine. Recent research indicates that ascorbate may also facilitate the
rate-limiting step in the synthesis of dopamine via recycling the enzyme cofactor tetrahydrobiopterin (Fig. 2)
[50]. This cofactor is required by the iron-containing enzyme tyrosine hydroxylase which hydroxylates the amino
acid L-tyrosine to form the dopamine precursor
L-DOPA. Some evidence also suggests that ascorbate

Vasopressin, also known as arginine vasopressin (AVP)
or antidiuretic hormone (ADH), is a peptide hormone
which is synthesised in the hypothalamus as a pre-prohormone and subsequently stored in the posterior pituitary as the mature hormone [57]. It is secreted in response
to decreased blood volume, decreased arterial pressure or
increased plasma osmolality, and interacts with specific
receptors expressed by vascular smooth muscle cells
(AVPR1a) and kidney collecting ducts (AVPR2) to cause
vasoconstriction and water retention [11]. The receptor
AVPR1b (or AVPR3) is expressed in the anterior pituitary,
and stimulation of this receptor by vasopressin enhances release of adrenocorticotrophic hormone (ACTH),
thereby acting synergistically with corticotrophin-releasing
hormone (CRH), and resulting in stimulation of corticosteroid synthesis in the adrenal cortex in response to stress
[11]. Circulating vasopressin levels increase dramatically
during the initial phase of septic shock, but this is followed
by a significant decline in the latter phase [58, 59]. Patients
in late-phase septic shock have significantly lower levels of
circulating vasopressin compared with patients in cardiogenic shock, despite similar hypotension [59]. The decline
in circulating vasopressin levels after the onset of septic
shock is due to depletion of pituitary stores and possibly
also impaired vasopressin synthesis [60].
Ascorbate is a cofactor for the copper-containing enzyme peptidylglycine α-amidating monooxygenase (PAM)
that is required for the endogenous synthesis of vasopressin [61]. It is of interest to note that the pituitary gland,
where the enzyme PAM is abundantly expressed, has the
highest levels of ascorbate in the body [53]. Thus, it is
conceivable that depletion of the PAM cofactor ascorbate during sepsis may contribute to the observed decrease in vasopressin biosynthesis [58–60]. Support for
a connection between ascorbate and vasopressin biosynthesis comes from an animal study whereby centrally
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Fig. 2 Ascorbate-dependent synthesis of the catecholamine vasopressors dopamine, norepinephrine and epinephrine. Ascorbate acts as a cofactor for
the metallo-enzyme dopamine hydroxylase, and also recycles the enzyme cofactor tetrahydrobiopterin. AA ascorbic acid, DHA dehydroascorbic acid,
BH4 tetrahydrobiopterin, BH2 dihydrobiopterin

administered ascorbate enhanced circulating levels of
vasopressin and induced antidiuresis (Table 1) [62].
Vasopressin is synthesised as a pre-pro-hormone which
undergoes sequential cleavage steps to produce provasopressin and finally a glycine-extended vasopressin
precursor. The carboxy-terminal glycine residue of the
vasopressin precursor subsequently undergoes posttranslational modification by the ascorbate-dependent
enzyme PAM to generate the active carboxy-amidated
hormone (Fig. 3). The enzyme comprises two domains: a
copper-dependent peptidylglycine α-hydroxylating monooxygenase domain, which converts glycine-extended peptides into a hydroxyglycine intermediate; and a peptidyl
α-hydroxyglycine α-amidating lyase domain, which
converts the hydroxyglycine intermediate into an

amidated product [61]. The carboxy-terminal amine
group of amidated peptides is essential for their biological activities [63].
Pro-vasopressin and copeptin, which lack the carboxyterminal amine present in mature vasopressin, have been
proposed as surrogate measures of the mature amidated
hormone because of their enhanced half-life in circulation [64, 65]. Pro-vasopressin and copeptin levels have
been measured in patients with septic shock and were
shown to be significantly associated with mortality,
higher levels being observed in non-survivors than in
survivors [64, 65]. Circulating copeptin levels are approximately 10-fold higher than those of vasopressin in
severe sepsis and septic shock [66]; however, it is not
known whether this is simply due to enhanced stability
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Fig. 3 Ascorbate-dependent synthesis of mature carboxy-terminal amidated vasopressin. Ascorbate is a cofactor for the metallo-enzyme
peptidylglycine α-amidating monooxygenase (PAM). AA ascorbic acid, DHA dehydroascorbic acid

of copeptin in circulation and/or decreased synthesis of
mature vasopressin. The assumption that pro-vasopressin/
copeptin levels reflect those of active vasopressin in a
stoichiometric manner would not hold true if posttranslational modification of glycine-extended vasopressin by PAM were affected through limited cofactor
availability. In support of this premise, critically ill patients with sepsis and systemic inflammatory response
syndrome (SIRS) have a significantly lower ratio of
vasopressin to copeptin than patients after cardiac

surgery [67]. Thus, pro-vasopressin/copeptin should
not be used as a surrogate marker for vasopressin levels
in patients with hypovitaminosis C or hypoxia, both of
which are common in severe sepsis and septic shock.

Conclusions
Ascorbate enhances the synthesis of the vasopressors
norepinephrine and vasopressin by acting as a cofactor
for their respective biosynthetic enzymes. As such, we
hypothesise that administration of high-dose ascorbate
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in conditions of hypovitaminosis C (e.g. severe sepsis
and septic shock) may support the endogenous synthesis
of these vasoactive compounds and thus ameliorate
the need for exogenously administered vasopressors.
Ascorbate-dependent vasopressor synthesis represents
a plausible physiological mechanism whereby ascorbate
could act as an adjuvant therapy for severe sepsis and
septic shock. Whether this mechanism translates into
improved patient outcomes requires testing in welldesigned clinical trials.
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